Teva Pharmaceutical Industries Limited

Minutza Leibovici

Ruth Tenengauzer

Yehudit Dolitzky

Yoseph Avezov

Dina Spivak

Ben-Zion Solomon

Judith Aronhime

Michael Fox

Rakefet Cohen

Marco Kordova

Anne Braunstein

Mira Kopel

Itamar Kanari

Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.

2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate

Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method.

Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof

A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.

Stable pergolide mesylate and process for making same

Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.

Stable pharmaceutical formulation comprising torsemide modification II

Growing community of inventors

Netanya, Israel

Minutza Leibovici